Edding Genor Group Holdings Limited (FRA:67N0)

Market Cap	369.76M
Revenue (ttm)	286.66M -3.6%
Net Income	28.20M -5.0%
EPS	0.01 -35.3%
Shares Out	n/a
PE Ratio	14.98
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,060
Open	0.1730
Previous Close	0.1760
Day's Range	0.1730 - 0.1730
52-Week Range	0.1520 - 0.4100
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About FRA:67N0

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial. It also provides Vancocin for mult...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,499
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 67N0

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error